NO20002481L - Kombinasjonsterapi for behandling av AIDS - Google Patents

Kombinasjonsterapi for behandling av AIDS

Info

Publication number
NO20002481L
NO20002481L NO20002481A NO20002481A NO20002481L NO 20002481 L NO20002481 L NO 20002481L NO 20002481 A NO20002481 A NO 20002481A NO 20002481 A NO20002481 A NO 20002481A NO 20002481 L NO20002481 L NO 20002481L
Authority
NO
Norway
Prior art keywords
combination
reverse transcriptase
aids
inhibitors
treatment
Prior art date
Application number
NO20002481A
Other languages
English (en)
Other versions
NO20002481D0 (no
Inventor
Joseph P Vacca
Jiunn H Lin
Kuang C Yeh
Jeffrey A Chodakewitz
Paul J Deutsch
William D Ju
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807938.7A external-priority patent/GB9807938D0/en
Priority claimed from GBGB9819590.2A external-priority patent/GB9819590D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20002481D0 publication Critical patent/NO20002481D0/no
Publication of NO20002481L publication Critical patent/NO20002481L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Kombinasjonen av HTV-proteaseinhibitoren forbindelse A og én eller flere nukleosidinhibitorer av revers transkriptase, ikke-nukleosidinhibitorer av revers transkriptase eller proteaseinhibitorer er anvendbar for inhibering av HIV-protease, inhibering av HIV-revers transkriptase, forebyggelse eller behandling av AIDS, enten som forbindelser, farmasøytisk aksepterbare salter eller estere, bestanddeler i farmasøytiske preparater, i kombinasjon eller ikke i kombinasjon med andre antivirale midler, immunmodulatorer, antibiotika eller vaksiner. Fremgangsmåter for behandling av AIDS og fremgangsmåter for forebyggelse eller behandling av HlV-infeksjon beskrives også.
NO20002481A 1997-11-13 2000-05-12 Kombinasjonsterapi for behandling av AIDS NO20002481L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6542197P 1997-11-13 1997-11-13
GBGB9807938.7A GB9807938D0 (en) 1998-04-15 1998-04-15 Combination therapy for the treatment of AIDS
US9094098P 1998-06-26 1998-06-26
GBGB9819590.2A GB9819590D0 (en) 1998-09-08 1998-09-08 Combination therapy for the treatment of aids
PCT/US1998/024097 WO1999025352A1 (en) 1997-11-13 1998-11-12 Combination therapy for the treatment of aids

Publications (2)

Publication Number Publication Date
NO20002481D0 NO20002481D0 (no) 2000-05-12
NO20002481L true NO20002481L (no) 2000-07-12

Family

ID=27451773

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002481A NO20002481L (no) 1997-11-13 2000-05-12 Kombinasjonsterapi for behandling av AIDS

Country Status (24)

Country Link
EP (1) EP1044000B1 (no)
JP (1) JP2001522889A (no)
KR (1) KR20010032055A (no)
CN (1) CN1285747A (no)
AR (1) AR013758A1 (no)
AT (1) ATE218866T1 (no)
AU (1) AU749795B2 (no)
BG (1) BG104507A (no)
BR (1) BR9814146A (no)
CA (1) CA2309164A1 (no)
CO (1) CO4970782A1 (no)
DE (1) DE69806062T2 (no)
EA (1) EA200000513A1 (no)
ES (1) ES2177103T3 (no)
HU (1) HUP0100365A3 (no)
ID (1) ID24922A (no)
IL (1) IL135994A0 (no)
IS (1) IS5481A (no)
NO (1) NO20002481L (no)
PE (1) PE20000020A1 (no)
PL (1) PL340430A1 (no)
SK (1) SK6842000A3 (no)
TR (1) TR200001938T2 (no)
WO (1) WO1999025352A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
AU2002355739A1 (en) 2001-07-30 2003-02-17 University Of Southern California Preparation and use of alpha-keto phosphonates
DK1583542T3 (da) * 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
GB2400553A (en) * 2003-04-14 2004-10-20 Cipla Ltd Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174921T3 (es) * 1993-12-15 2002-11-16 Merck & Co Inc Inhibidores de la proteasa del vih.

Also Published As

Publication number Publication date
IS5481A (is) 2000-05-09
JP2001522889A (ja) 2001-11-20
PL340430A1 (en) 2001-02-12
CN1285747A (zh) 2001-02-28
DE69806062D1 (de) 2002-07-18
IL135994A0 (en) 2001-05-20
PE20000020A1 (es) 2000-01-27
CO4970782A1 (es) 2000-11-07
AR013758A1 (es) 2001-01-10
BR9814146A (pt) 2000-10-03
HUP0100365A2 (hu) 2002-05-29
NO20002481D0 (no) 2000-05-12
AU749795B2 (en) 2002-07-04
TR200001938T2 (tr) 2001-07-23
AU1522599A (en) 1999-06-07
ES2177103T3 (es) 2002-12-01
EP1044000A1 (en) 2000-10-18
CA2309164A1 (en) 1999-05-27
EA200000513A1 (ru) 2000-10-30
SK6842000A3 (en) 2000-12-11
KR20010032055A (ko) 2001-04-16
HUP0100365A3 (en) 2002-06-28
DE69806062T2 (de) 2003-03-20
ID24922A (id) 2000-08-31
WO1999025352A1 (en) 1999-05-27
BG104507A (bg) 2001-03-30
ATE218866T1 (de) 2002-06-15
EP1044000B1 (en) 2002-06-12

Similar Documents

Publication Publication Date Title
NO953308L (no) Inhibitorer av HIV-reverstranskriptase
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
NO954427L (no) Hiv-proteaseinhibitorer som er anvendbare for behandling av AIDS
DK1293207T3 (da) Anvendelse af ritonavir (ABT-538) til forbedring af farmokokinetikken af lægemidler, som metaboliseres af cytochrome P450 i en fremgangsmåde til at behandle AIDS
AU2725392A (en) Hiv protease inhibitors
NO20053455L (no) Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer
NO953876D0 (no) HIV-proteaseinhibitorer som er anvendbare for behandling av AIDS
NO962000L (no) Prolegemidler av en inhibitor av HIV-protease
WO2006083553A3 (en) Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase
DE69430385T2 (de) Hiv-proteaseinhibitoren
NO960775L (no) Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner
NO20002481L (no) Kombinasjonsterapi for behandling av AIDS
ZA991029B (en) Composition and methods for treatment of hiv infections.
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
NO965591L (no) Kombinasjonsbehandling av HIV-infeksjon
NO981898L (no) Anvendelse av flupirtin for forhindring og behandling av sykdommer som er forbundet med skade pÕ det hematopotiske cellesystem
NO951608D0 (no) Anvendelse av BHAP-forbindelser i kombinasjon med andre ikke-nukleoside reverstranskriptaseinhibitorer for behandling av HIV-infeksjon
DK0774969T3 (da) HIV-proteaseinhibitor kombination
NO944208L (no) Nye kinazoliner som inhibitorer av HIV-reverstranskriptase
AU7076600A (en) Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
ECSP961660A (es) Terapia combinada para infeccion por vih
NO931338L (no) Forbindelser og fremgangsmaater for inhibering av hiv og beslektede virus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application